Payment overview · 2025
General Payments
$415.07
24 reported records · 12 companies
Healthcare provider profile · identity verified
Joshua Chapman, MD
Allopathic & Osteopathic Physicians|Family Medicine · BELLEVILLE, KS · NPI 1689178956
Verified facts
What the public records show
CMS Open Payments records show Joshua Chapman, MD received $415.07 in general payments during 2025 across 24 reported records.
Paratek Pharmaceuticals, Inc. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.53 | 24.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.04 | 14.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.33 | 10.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.11 | 10.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.44 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.73 | 6.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.43 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.64 | 4.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.58 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.32 | 3.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.00 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.92 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.07 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $102.53 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.04 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.33 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.73 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 110 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
110 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 211 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 34 |
| Furosemide | Furosemide | 137 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 24 |
| Montelukast Sodium | Montelukast Sodium | 122 | 20 |
| Gabapentin | Gabapentin | 117 | 27 |
| Potassium Chloride | Potassium Chloride | 112 | 21 |
| Vraylar | Cariprazine Hcl | 110 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 23 |
| Lisinopril | Lisinopril | 103 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 21 |
| Carvedilol | Carvedilol | 100 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 25 |
| Omeprazole | Omeprazole | 86 | 17 |
| Meloxicam | Meloxicam | 85 | 18 |
| Farxiga | Dapagliflozin Propanediol | 79 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 12 |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Simvastatin | Simvastatin | 62 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 12 |
| Trazodone Hcl | Trazodone Hcl | 57 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 27 |
| Prednisone | Prednisone | 56 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 11 |
| Azithromycin | Azithromycin | 53 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Famotidine | Famotidine | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Metformin Hcl | Metformin Hcl | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | 11 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 32 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Kerendia | Finerenone | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 11 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Buprenorphine | Buprenorphine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Dexamethasone | Dexamethasone | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 18 |
| Austedo Xr | Deutetrabenazine | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Naproxen | Naproxen | 16 | 11 |
| Ozempic | Semaglutide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Victoza 2-Pak | Liraglutide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.07 · 24 records | Paratek Pharmaceuticals, Inc. | AIRSUPRA, CAPLYTA, EVENITY, Kerendia, Korlym, NUZYRA, QULIPTA, REXULTI, TONMYA, UBRELVY, VRAYLAR, XHANCE, XIFAXAN, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error